Phase 3 Stomach Cancer Trial, Recruiting NCT05303714 Sponsor: Azienda Ospedaliera Universitaria Integrata Verona Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT05303714
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have stomach cancer that can be removed by surgery, and a keyhole (laparoscopy) procedure has confirmed that either cancer cells are present in the fluid around your abdomen, or the cancer has spread slightly into the abdominal lining but only to a limited degree (a spread score of 6 or less)
  • You have read and signed a form agreeing to take part in the trial
  • You are generally well enough to carry out light daily activities — you may not be fully active but you are not bedridden (confirm with trial site)

Who may not be able to join:

  • The cancer has spread to areas outside the abdominal lining (for example, to the lungs or liver)
  • The cancer has spread more extensively across the abdominal lining (a spread score above 6)
  • The tumour is located where the food pipe meets the stomach in a way that is considered more related to the food pipe than the stomach (confirm with trial site)
  • You have had a serious allergic reaction to the chemotherapy drugs cisplatin or doxorubicin in the past
  • The tumour is causing bleeding or a blockage that requires urgent surgery to relieve symptoms
  • You have a very severe overall physical condition that makes surgery very high risk (confirm with trial site)
  • Your tumour tests positive for certain biological markers (EBV, MSI, or HER2) on biopsy samples (confirm with trial site)
  • You are pregnant or currently breastfeeding
  • You have a medical reason that prevents you from safely receiving any of the chemotherapy drugs used in this trial
  • Your liver is not working well enough, based on specific blood test results being too high
  • You have had a stroke in the last 6 months
  • You have had a heart attack in the last 6 months
  • You have moderate or severe heart failure
  • Your white blood cell count is too low, based on a blood test
  • Your platelet count (cells that help blood clot) is too low, based on a blood test
  • You currently have an active hepatitis B or C infection
  • You have HIV infection
  • Your kidneys are not filtering your blood well enough, based on a specific measurement of kidney function

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Francesco Casella, General and Upper GI Surgery, University of Verona

Phone: +390458123123

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Registry
ClinicalTrials.gov
Start date
31 March 2022
Est. completion
30 September 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Secondary Resectability Rate (percent)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov